Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Castera

Showing results (21-30 of 200) with videos related to

Pageof 20
Sort By:
Best Practice & Research. Clinical Gastroenterology|April 19, 2011
Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver diseaseLaurent Castera
Gastroenterology|April 28, 2012
Noninvasive methods to assess liver disease in patients with hepatitis B or CLaurent Castera
Clinical and Molecular Hepatology|December 6, 2022
Identification of high-risk subjects in nonalcoholic fatty liver diseaseChristiane Stern, Laurent Castera
Lancet (London, England)|April 27, 2010
Non-invasive assessment of liver fibrosis: are we ready?Laurent Castera, Massimo Pinzani
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?Laurent Castera, Pierre Bedossa
Gut|June 29, 2010
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?Laurent Castera, Massimo Pinzani
Hepatology International|October 27, 2016
Non-invasive diagnosis of hepatic steatosisChristiane Stern, Laurent Castera
Seminars in Liver Disease|July 14, 2022
Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLDLaurent Castera, Jérôme Boursier
Annales De Biologie Clinique|April 19, 2019
[Non-invasive biomarkers of fibrosis for the screening of patients with metabolic steatopathy (NAFLD): a significant role for all biologists]Katell Peoc'h, Laurent Castera
Hepatology (Baltimore, Md.)|January 11, 2023
Diabetes and cirrhosis: Current concepts on diagnosis and managementLaurent Castera, Kenneth Cusi
Pageof 20

Showing results (21-30 of 200) with videos related to

Sort By:
Pageof 20
Best Practice & Research. Clinical Gastroenterology|April 19, 2011
Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver diseaseLaurent Castera
Gastroenterology|April 28, 2012
Noninvasive methods to assess liver disease in patients with hepatitis B or CLaurent Castera
Clinical and Molecular Hepatology|December 6, 2022
Identification of high-risk subjects in nonalcoholic fatty liver diseaseChristiane Stern, Laurent Castera
Lancet (London, England)|April 27, 2010
Non-invasive assessment of liver fibrosis: are we ready?Laurent Castera, Massimo Pinzani
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?Laurent Castera, Pierre Bedossa
Gut|June 29, 2010
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?Laurent Castera, Massimo Pinzani
Hepatology International|October 27, 2016
Non-invasive diagnosis of hepatic steatosisChristiane Stern, Laurent Castera
Seminars in Liver Disease|July 14, 2022
Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLDLaurent Castera, Jérôme Boursier
Annales De Biologie Clinique|April 19, 2019
[Non-invasive biomarkers of fibrosis for the screening of patients with metabolic steatopathy (NAFLD): a significant role for all biologists]Katell Peoc'h, Laurent Castera
Hepatology (Baltimore, Md.)|January 11, 2023
Diabetes and cirrhosis: Current concepts on diagnosis and managementLaurent Castera, Kenneth Cusi
Pageof 20